Does the Multidrug-Resistance Modulator Cyclosporin a Increase the Cardiotoxicity of High-Dose Anthracycline Chemotherapy?

Cyclosporin A has heterogeneous effects on anthracycline-related cardiotoxicity and can prevent multidrug-resistance (MDR). The aim of this study was to explore whether the coadministration of cyclosporin A is accompanied by an increase in cardiotoxicity. Forty-three patients (27 male, 16 female, ag...

Full description

Saved in:
Bibliographic Details
Published in:Acta oncologica 1997, Vol.36 (7), p.735-740
Main Authors: Eising, Ernst G., Gries, Pascal, Eggert, Jochen, Scheulen, Max E.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Analysis of Variance
Animals
Antibiotics, Antineoplastic - adverse effects
Antibiotics, Antineoplastic - therapeutic use
Biological and medical sciences
Cyclosporine - pharmacology
Doxorubicin - adverse effects
Doxorubicin - therapeutic use
Drug Resistance, Multiple
Drug Synergism
Drug toxicity and drugs side effects treatment
Epirubicin - adverse effects
Epirubicin - therapeutic use
Female
Heart - drug effects
Humans
Immunosuppressive Agents - pharmacology
Male
Medical sciences
Middle Aged
Neoplasms - drug therapy
Pharmacology. Drug treatments
Toxicity: cardiovascular system
Ventricular Function, Left - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cyclosporin A has heterogeneous effects on anthracycline-related cardiotoxicity and can prevent multidrug-resistance (MDR). The aim of this study was to explore whether the coadministration of cyclosporin A is accompanied by an increase in cardiotoxicity. Forty-three patients (27 male, 16 female, age: 18-67 yrs (mean: 47.5 yrs, SD: 11.6 yrs)) received 177 radionuclide ventriculography examinations (RNV/177 at rest, 133 at stress) before and during chemotherapy with either doxorubicin (n = 23) or epirubicin (n = 20). RNV studies were applied up to 11 times in the follow-up of the patients. A maximum of 10 courses of chemotherapy was performed. In the doxorubicin group only, the age of the patients and the cumulative dose of the chemotherapeutic agent had a significant negative impact on left ventricular ejection fractions, whereas cyclosporin A had a significant positive influence (multiple analysis of regression, p < 0.05). Cyclosporin A did not cause any significant increase in cardiotoxicity in our patients.
ISSN:0284-186X
1651-226X
DOI:10.3109/02841869709001347